The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …

Follicular lymphoma is an indolent and usually incurable disease. It has been, therefore,
traditionally approached either by watch and wait or with single-agent treatments with the …

Although the introduction of anti-CD20 monoclonal antibodies has improved the outcome of
patients with follicular lymphoma, a curative treatment is still not available. Many questions …

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to
differences in clinical, laboratory, and disease parameters. Although generally considered …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

Follicular lymphoma (FL) is a common B-cell malignancy characterized by relatively indolent
growth and incurability with an expected lifetime course of serial intermittent treatment …

Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …

Over the last few years, there have been many changes in the management of patients with
follicular lymphoma, resulting in improvements in progression-free survival and quality of …

Simple Summary Follicular lymphoma (FL)—a common, indolent, and usually non-curable B-
cell non-Hodgkin lymphoma—is frequently treated with cytotoxic chemotherapy with anti …

Follicular lymphoma is often managed as an incurable disease. However, a substantial and
growing fraction of patients are achieving long‐term disease‐free survival from aggressive …